A retrospective cohort study presented at ENDO 2026 found adults with type 2 diabetes taking semaglutide had about 15% lower fracture risk than those using other diabetes or weight-loss medications. Researchers, led by Stanford's Sun H. Kim, aimed to determine whether the effect was unique to semaglutide or related to weight-loss differences. The findings follow earlier data showing semaglutide linked to 26% lower fracture risk than sleeve gastrectomy. More research is needed to assess whether other incretin medications confer similar benefits.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.